Pharmaceutical Products / Drugs Technology Offers

Technology Categories

By Type

Arkadiusz Rudawski, PhD posted this:
Technology Broker at Center for Technology Transfer, Cracow University of Technology

A modern form of formulation on burn wound healing, containing bioactive lavender oil (Lavandula angustifolia)The subject of the invention will be a nanoformulation containing as a therapeutic ingredient bioactive lavender oil (Lavandula angustifolia).

Alireza Daneshvar posted this:
Pharmacy Student and Researcher at Tehran University of Medical Sciences

COVID-19 Rapid Diagnostic Kit Designing and developing vaccines, cures and diagnostic kits can be considered as the first priority for every country which is in the first line of fighting against coronavirus. Now there is only PCR test and IgG/IgM test for COVID-19 assessment. One of the most important problems of this diagnostic test is the time needed by the device to detect infected persons. This problem makes big companies in the field of pharmaceutical and medical devices manufacturing to design and develop rapid test kits. Our research team found that there are some specific proteins on the viral membrane which can make some reagents undergo a specific chemical reaction. Every reaction has a specific product related to substrates, so by detection of products with indicator reagents we are able to identify the virus in saliva. Indicator reagents usually change the reaction mixture color so by color change we can approve that the person is infected by COVID-19.

COVID-19 Rapid Diagnostic Kit

Covid-19 Innovation Challenges by Innoget posted this:

Expertise in molecular biology either experimentally or computationally The Institut de Biotecnologia i de Biomedicina (IBB) was created in 1970 as a research institute of the Universitat Autònoma de Barcelona (UAB) to promote fundamental biological research. In the year 2000, the focus of research evolved towards the Biotechnology and Biomedicine fields, with the aim of advancing scientific findings into translational results. At present, the Institute hosts 18 research groups organised into 3 programmes and working in 7 areas of expertise: • Bioinformatics • Cellular Biology • Structural Biology • Genomics • Immunology • Microbiology • Proteomics. This multidisciplinary character, one of the most relevant characteristics of the IBB, allows for a broad approach to biological problems, both basic and applied. The IBB is also highly engaged in academic training at the undergraduate and postgraduate levels.

Expertise in molecular biology either experimentally or computationally

IBB-UAB posted this:

Expertise in molecular biology either experimentally or computationally The Institut de Biotecnologia i de Biomedicina (IBB) was created in 1970 as a research institute of the Universitat Autònoma de Barcelona (UAB) to promote fundamental biological research. In the year 2000, the focus of research evolved towards the Biotechnology and Biomedicine fields, with the aim of advancing scientific findings into translational results. At present, the Institute hosts 18 research groups organised into 3 programmes and working in 7 areas of expertise: • Bioinformatics • Cellular Biology • Structural Biology • Genomics • Immunology • Microbiology • Proteomics. This multidisciplinary character, one of the most relevant characteristics of the IBB, allows for a broad approach to biological problems, both basic and applied. The IBB is also highly engaged in academic training at the undergraduate and postgraduate levels.

Expertise in molecular biology either experimentally or computationally

TEC Edmonton posted this:

Inhibitors of Viral Infectivity: Amphipathic Nucleoside Derivatives as Fusion Inhibitors A series of small pharmacological molecules have been discovered to be potent and non-cytotoxic inhibitors of viral fusion. The inhibitors act on the non-virally encoded lipids in the virion envelope. These molecules are rigid amphipathic compounds of inverted cone shape which locate to the outer leaflets of virion envelopes, creating a physical barrier to viral envelope and cell membrane fusion. These amphipathic nucleoside derivatives can serve as potential antiviral or therapeutic agents against herpes, HIV, influenza, hepatitis B & C, poxvirus and other DNA or RNA enveloped viruses. They can potentially be used as prophylactic ingredients in creams, lotions, gels and as antiviral disinfectants.

Inhibitors of Viral Infectivity: Amphipathic Nucleoside Derivatives as Fusion Inhibitors

Covid-19 Innovation Challenges by Innoget posted this:

Inhibitors of Viral Infectivity: Amphipathic Nucleoside Derivatives as Fusion Inhibitors A series of small pharmacological molecules have been discovered to be potent and non-cytotoxic inhibitors of viral fusion. The inhibitors act on the non-virally encoded lipids in the virion envelope. These molecules are rigid amphipathic compounds of inverted cone shape which locate to the outer leaflets of virion envelopes, creating a physical barrier to viral envelope and cell membrane fusion. These amphipathic nucleoside derivatives can serve as potential antiviral or therapeutic agents against herpes, HIV, influenza, hepatitis B & C, poxvirus and other DNA or RNA enveloped viruses. They can potentially be used as prophylactic ingredients in creams, lotions, gels and as antiviral disinfectants.

Inhibitors of Viral Infectivity: Amphipathic Nucleoside Derivatives as Fusion Inhibitors

Pascal Mayer posted this:
CEO at Alphanosos

Alphanosos rapid discovery technology against COVID 19 Alphanosos’ AI guided rapid discovery technology, validated in antimicrobials and anticancer, is expected to develop within 3 weeks of experimental work with a virology partner an anti-COVID-19 treatment composed of a synergistic mix of extracts of edible plants, chosen for being available in large amounts and with good traceability. Such treatment is, therefore, and also thanks to the innovative elaboration process, immediately available to enter large curative clinical trials, to be followed by country-wide deployment in a matter of weeks, for curative and for preventive goals (because of safety which is guaranteed by the edible nature of the mix).

Alphanosos rapid discovery technology against COVID 19

Universitat Politècnica de Catalunya - UPC posted this:

Fast cardiovascular condition assessment An easy-to-use and affordable system able to determine several cardiovascular parameters from unsupervised measurements easily obtained at hands or feet.

Fast cardiovascular condition assessment

Universitat Politècnica de Catalunya - UPC posted this:

Enzymatic aqueous preparation for the surface functionalization of paper or cellulosic substrates A new biotechnological product for the chemical modification of the surface of cellulosic substrates has been patented. The bioproduct is obtained from an enzyme-mediator system, and several properties can be easily conferred to substrates applying very low concentrations of this enzymatic product in their surface. Partners to further develop the product and/or to establish commercial agreements along with technical cooperation are sought.

Enzymatic aqueous preparation for the surface functionalization of paper or cellulosic substrates

Ivan Rodriguez Rosello posted this:
Licensing Manager at Universidad de Alicante

Antibacterial alternative to antibiotics, with high specificity against Escherichia coli The "Molecular Microbiology" research group at the University of Alicante has modified several phage proteins (Poll-N and UK-C) that have high specificity against Escherichia coli (E. coli), but not against other Gram-negative (G-) bacteria. For these reasons, their use as a specific antimicrobial against E. coli is potentially interesting, especially in the case of contaminated food, cosmetics or water. It would also be useful in the treatment of diseases (infections) caused by E. coli. The presence of a histidine tail attached to the phage proteins not only facilitates their purification but also improves lysis efficiency without the need of cell permeabilization treatments. Companies interested in the commercial exploitation of the technology through license agreements and/or technical cooperation are sought.

Antibacterial alternative to antibiotics, with high specificity against Escherichia coli

University of Vigo posted this:

Procedure for the extraction of biosurfactants contained in corn steep liquors Nowadays, most of the pharmaceutical and cosmetic products in the market contain chemically synthesized surfactants in its composition. In many cases, these surfactants are the same as those used in regular cleanup activities. In order to get more natural and biocompatible products, it would be interesting to include natural surfactants instead of chemical surfactants in the preparation of these pharmaceutical and cosmetic products. These biosurfactants are also present in the formulation of greener nanoparticles, replacing the chemical surfactants currently used in the preparation thereof. Most biosurfactants have antimicrobial activity, which would improve the properties of certain nanoparticles, as well as many pharmaceutical and cosmetic products. The main disadvantage of biosurfactants industrial production is related to the high cost compared to chemically synthesized surfactant production. The solution proposed by the Chemical Engineering research group at the University of Vigo, is the development of eco-friendly simple extraction of biosurfactant from a corn wet-milling industry byproduct, such as corn wash liquors, better known as "corn steep liquor (CSL)", which could compete in terms of cost production with its chemical counterparts.

National Cancer Institute CRO Aviano posted this:

HPLC device for high-volume samples analysis Fluidic device that allows high sample volume injection in HPLC systems and provides an automated purification step, reducing sensitivity problems and facilitating the analysis of extracted compounds from complex matrix.

National Cancer Institute CRO Aviano posted this:

CHEMIOTHERAPY: IMATINIB DRUG MONITORING The effectiveness of many anticancer drugs varies greatly from patient to patient, with risks of incorrect dosages and adverse side effects. The invention provides for the first time an electrochemical method to measure the concentration of the drug Imatinib in patient's plasma and then to establish the optimal dose, with an on site test readable in real time.

National Cancer Institute CRO Aviano posted this:

Mechanisms of p53 inactivation in TP53 wild type tumors and factors affecting sensitivity to MDM2 inhibitors The research group led by Dr Roberta Maestro demonstrated that the overexpression of the protein Twist, detectable in a large fraction of sarcomas but also in a fraction of carcinomas, facilitates the MDM2-mediated degradation of p53 by making p53 more susceptible to MDM2 attack. The p53:MDM2 interplay is the target of a number of compounds currently under clinical trials. These compounds (MDM2i) are aimed at alleviating p53 from MDM2-mediated degradation and hence at restoring the p53 tumor suppressive activity. Maestro and coworkers gathered data indicating that the expression of Twist may significantly impact on the activity of these drugs.

UACOOPERA University of Aveiro posted this:
Technology Transfer Office at uacoopera

Immunoglobulin Y Purification, Its Products And Uses This invention describes a purification process of immunoglobulin Y from egg yolk in three stages, by applying precipitation methods, liquid-liquid extraction and ultracentrifugation. The present process allows to obtain immunoglobulin Y of high quality and with a purity >95%, in a simple and economic way, and applicable at an industrial scale.

Immunoglobulin Y Purification, Its Products And Uses

1
2
3
4
5